Skip to content

Hemodynamic monitoring guided the treatment of inotropic drugs in patients with heart failure.

Hemodynamic monitoring guided the treatment of inotropic drugs in patients with heart failure.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065270
Enrollment
Unknown
Registered
2022-11-01
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

control group:The treatment of inotropic drugs was managed at the discretion of the attending physician according to clinical experience.
PiCCO group:The hemodynamic parameters were used to guide the treatment of inotropic drugs.

Sponsors

Shanghai East Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. age>=18 years old; 2. signed the informed consent; 3. patients diagnosed with heart failure.

Exclusion criteria

Exclusion criteria: 1. Extensive peripheral vascular disease; 2. Severe valve disease; 3. Patient treated with extracorporeal membrane oxygenation (ECMO); 4. Pregnant or lactating women; 5. Combined with mechanical complications of the heart.

Design outcomes

Primary

MeasureTime frame
Major adverse cardiovascular events;

Secondary

MeasureTime frame
Length and cost of hospitalization;Duration of instrument-assisted treatment during hospitalization;Duration of inotropes, diuretics, vasopressors, or vasodilators during hospitalization;Changes of parameters related to cardiac function;Complications such as hemorrhage, hematoma, embolism and infection;

Countries

China

Contacts

Public ContactJieyun You

Shanghai East Hospital

youjieyun1118@hotmail.com+86 13917791748

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026